Hjem › Småcellet lungekreft › North Carolina
Kliniske studier for Småcellet lungekreft i North Carolina
16 studier for Småcellet lungekreft søker deltakere på steder i North Carolina.
Byer i North Carolina
Offisiell studietekst (engelsk)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Duke University, Durham
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT04585750DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Cape Fear Valley Cancer Center, Fayetteville
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT07472517A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
- GSK Investigational Site, Wilson
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07099898DESTINY-PANTUMOUR04
- Research Site, Durham
- Research Site, Wilson
RekruttererObservasjonsstudie
Alder 18 til 130 · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07124000A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- FirstHealth of the Carolinas- Speciality Center /ID# 279857, Pinehurst
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07365241A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Duke Cancer Center Durham, Durham
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07488676Study of Trilaciclib and Lurbinectidin
- Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 21. sep. 2026 · NCT05578326A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
- Duke Cancer Institute, Durham
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT07325136A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Duke Cancer Institute, Durham
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 11. sep. 2026 · NCT06646276A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Huntersville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 6. aug. 2026 · NCT07749586A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- University of North Carolina at Chapel Hill, Chapel Hill
- Duke University Medical Center, Durham
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 15. jul. 2026 · NCT05652686Tempus Small Cell Lung Cancer Observational Study (Sculptor)
- University of North Carolina, Chapel Hill
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 15. jun. 2026 · NCT05257551Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
- FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. mar. 2026 · NCT06769126Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC
- Salisbury W.G. (Bill) Hefner VA Medical Center, Salisbury, NC, Salisbury
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. mar. 2026 · NCT06681220Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Carolina BioOncology Institute, Huntersville
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 18. feb. 2026 · NCT07030257Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
- Lineberger Comprehensive Cancer Center, Chapel Hill
RekruttererTidlig fase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 5. feb. 2026 · NCT05620342Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.